Selecta Biosciences (SELB) Tops Q2 EPS by 16c

Selecta Biosciences (NASDAQ: SELB) reported Q2 EPS of $0.04, $0.16 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $6.24 million.

For earnings history and earnings-related data on Selecta Biosciences (SELB) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c